HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response

Journal of Immunology

Volumn 165, Issue 8, 2000, Pages 4710-4717

  Weissman, D ^a   Ni, H ^a   Scales, D ^a   Dude, A ^a   Capodici, J ^a   McGibney, K ^a   Abdool, A ^a   Isaacs, S N ^a   Cannon, G ^a   Kariko, K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CORE PROTEIN; GAG PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA;

ANTIGEN PRESENTING CELL; ARTICLE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0034667917     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.8.4710     Document Type: Article

References (69)

1. New millenium: The need for new vaccines
2. The dendritic cell system and its role in immunogenicity
3. + CTLs from naive precursors
4. Recent advances in the study of dendritic cells and follicular dendritic cells
5. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
6. + T cell responses associated with control of viremia
7. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
8. Progress in the development of an HIV-1 vaccine
9. New prospects for the development of a vaccine against human immunodeficiency virus type 1: An overview
10. DNA-based immunization by in vivo transfection of dendritic cells
11. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
12. + T cells after gene gun immunization
13. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells
14. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
15. Immunotherapy of cancer with dendritic-cell-based vaccines
16. New trends in the development of cancer vaccines
17. The coming of age of tumour immunotherapy
18. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy
19. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
20. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro
21. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
22. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro
23. Class I MHC-peptide interaction: Structural and functional aspects
24. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells
25. Quantitative analysis of the immunopotency of genetically transfected dendritic cells
26. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
27. Envelope glycoproteins of human immunodeficiency virus type 1: Profound influences on immune functions
28. HIV-1 Tat: Immunosuppression via TGF-βI induction
29. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
30. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: A new modality for vaccination
31. Characterization of a messenger RNA polynucleotide vaccine vector
32. Polynucleotide-mediated immunization therapy of cancer
33. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
34. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
35. Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens
36. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
37. Dendritic cells express and use multiple HIV coreceptors
38. Cleavage of HIV-1 gag polyprotein synthesized in vitro: Sequential cleavage by the viral protease
39. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
40. The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation
41. Complete nucleotide sequences of functional clones of the AIDS virus
42. Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA
43. Compact, synthetic, vaccinia virus early/late promoter for protein expression
44. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria
45. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides
46. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy
47. T cell activation determined by T cell receptor number and tunable thresholds
48. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells
49. The effect of temperature and protein synthesis on the renaturation of firefly luciferase in intact H9c2 cells
50. MHC class I antigen processing pathways
51. Antigen presentation by MHC class II molecules: Invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture
52. Antigen processing by proteasomes: Insights into the molecular basis of crypticity
53. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
54. + T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
55. + dendritic cells
56. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
57. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
58. Polyriboinosinic polyribocytidylic acid (poly(1:C)) induces stable maturation of functionally active human dendritic cells
59. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily
60. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
61. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
62. + T lymphocyte responses in vitro using dendritic cells
63. Cellular and molecular barriers to gene transfer by a cationic lipid
64. Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA
65. Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression
66. RNA melanoma vaccine: Induction of antitumor immunity by human glycoprotein 100 mRNA immunization
67. Cancer therapy using a self-replicating RNA vaccine
68. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies